Elutia Inc. reported a net loss of $15.9 million for the fiscal year ending December 31, 2025, a significant improvement from a loss of $45.3 million in the previous year. The company’s total net sales decreased by 15% to $12.3 million, down from $14.5 million in 2024. This decline was primarily attributed to a drop in sales from its Women’s Health segment, particularly the SimpliDerm product, which faced challenges as some physician users transitioned to hospitals where the product was not available. Despite the overall sales decline, the company noted an increase in sales from its Cardiovascular segment, which rose by 8.3% to $3.2 million.
In 2025, Elutia completed the divestiture of its cardiac implantable electronic device (CIED) business to Boston Scientific Corporation and Cardiac Pacemakers Inc. for up to $88 million, which included a cash payment of $80.4 million at closing. This transaction allowed Elutia to fully repay its SWK Loan Facility, eliminating approximately $27.8 million in debt. The company also sold its Orthobiologics business to Berkeley Biologics in November 2023, receiving $14.6 million upfront and the potential for up to $20 million in earn-out payments based on future sales.
Operationally, Elutia is focusing on advancing its drug-eluting biomatrix (DEB) platform, particularly the development of NXT-41 and NXT-41x, which are designed to address complications in reconstructive surgeries. The company has increased its research and development expenses to $4.2 million, reflecting its commitment to these new product lines. As of December 31, 2025, Elutia had 26 employees, a reduction from previous years, as the company continues to streamline operations following its divestitures.
Looking ahead, Elutia anticipates ongoing operating losses as it invests in the development and commercialization of its new products. The company expects to seek additional capital to support its operations and product development efforts. Elutia is also preparing for potential FDA approvals for its new products, with expectations for NXT-41 clearance in the second half of 2026 and NXT-41x by mid-2027. The company’s future performance will depend on its ability to successfully navigate regulatory processes and achieve market acceptance for its innovative products.
About ELUTIA INC.
Elutia Inc. develops regenerative medicine products focused on device protection, women's health, and cardiovascular repair. Its offerings include bioenvelopes with antimicrobial properties and acellular dermal matrices to reduce complications like infection, migration, and fibrosis. The company leverages proprietary tissue engineering, strategic partnerships, and a scalable manufacturing model to serve healthcare providers, aiming to improve surgical outcomes and establish standards in implantable device and tissue reconstruction markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.